A study demonstrates that double inhibition is the most effective treatment for a rare inflammatory disease.

Published Date: 13 Mar 2024

Up to 40% of people who have hemophagocytic lymphohistiocytosis (HLH), a rare and frequently aggressive syndrome of hyperactive inflammation, will not survive. Scientists at St. Jude Children's Research Hospital has demonstrated that a medication that inhibits.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot